Navigation Links
Lycera Initiates Phase 1 Clinical Trial of LYC-30937, a First-In-Class ATPase Modulator for Inflammatory Bowel Disease
Date:4/30/2015

NEW YORK and ANN ARBOR, Mich., April 30, 2015 /PRNewswire/ -- Lycera Corp., a biopharmaceutical company developing breakthrough immunomodulatory medicines to treat autoimmune diseases and cancer, today announced the initiation of a Phase 1 clinical trial of LYC-30937 in healthy volunteers.  LYC-30937 is an oral gut-directed ATPase modulator that is being studied for the treatment of inflammatory bowel disease (IBD).  LYC-30937 is designed to selectively induce cell death (apoptosis) in disease-causing immune cells, sparing normal cells. LYC-30937 was discovered and developed by Lycera based on technology licensed from the University of Michigan; the company maintains full worldwide development and commercial rights.

"The initiation of a clinical program for LYC-30937 marks a major milestone for Lycera.  This is our first program to enter the clinic, as well as the first ATPase modulator to commence clinical testing," said Paul Sekhri, President and CEO of Lycera Corp.  "Lycera is dedicated to advancing a portfolio of drugs based on breakthrough science that have the potential to offer substantial advances for patient treatment.  We are proud of the progress of our lead program, and look forward to further accelerating additional candidates in our pipeline."  In mid-2016, Lycera expects to initiate clinical studies for its lead immune-oncology product candidate, an agonist of RORgamma, as well as an anti-fibrotic agent, a highly selective ROCK2 (rho-associated kinase II) inhibitor.

"Inflammatory bowel diseases including ulcerative colitis and Crohn's disease, are chronic, life-long autoimmune diseases with significant medical needs and the potential for life-threatening complications," said Dr. H. Jeffrey Wilkins, Chief Medical Officer of Lycera.  "In contrast to current injectable treatments, LYC-30937 is an oral agent that acts on a novel target, locally in the gut.  Our development plan looks to demonstrate whether the promising preclinical data translates into an effective and well-tolerated novel treatment for patients with ulcerative colitis and inflammatory bowel disease.  We are excited to initiate the clinical program and anticipate the completion of the study by year end 2015."

About Lycera
Lycera is a biopharmaceutical company developing novel oral immune modulators for the treatment of autoimmune diseases and cancer. Based on successful progress of its world-class R&D platform, including expertise in immune metabolism, cell signaling, and immune cell differentiation, Lycera is commencing multiple clinical programs in 2015 and 2016. The company is advancing an oral, gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, which is currently in Phase 1 clinical testing, and oral RORgamma agonists for diverse applications in immune-oncology. In addition, Lycera has established two collaborations with Merck to discover, develop and commercialize small molecule therapies for autoimmune disorders. Lycera's leadership possesses deep experience in drug discovery, development, and commercialization and has established close relationships with renowned thought leaders and clinical researchers worldwide. Lead investors in Lycera include InterWest Partners, ARCH Venture Partners, Clarus Ventures, and EDF Ventures.

CONTACTS:

For Media:
Justin Jackson, Burns McClellan, on behalf of Lycera Corp.
212-213-0006, ext. 327
jjackson@burnsmc.com


'/>"/>
SOURCE Lycera Corp.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Lycera Announces Milestone in Merck Collaboration
2. Lycera to Present at the 2015 American Association for Cancer Research (AACR) Annual Meeting
3. Lycera Announces Research Showing Promising Anti-Cancer Activity of Novel, Oral Immunotherapy Candidates
4. Lycera Announces Presentation of Data on Anti-Tumor Activity of Novel Synthetic RORgamma Agonists at Society for Immunotherapy of Cancer Meeting
5. Benitec Biopharma Doses Fifth Patient And Initiates Additional Trial Site For Hepatitis C Trial
6. Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1450 in Staphylococcal Skin Infections
7. Bionomics Initiates Phase II Clinical Trial of BNC210 for Treatment of Anxiety
8. Edison Initiates Coverage on Tonix Pharmaceuticals
9. Rhythm Initiates Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis
10. Obalon Initiates U.S. Pivotal Trial of Novel Weight Loss Balloon
11. Edison Initiates Coverage on Threshold Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
(Date:10/11/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an ... Puerto Rico , where the company ... Following a comprehensive onsite assessment, ... damage, temporary loss of power and minimal water damage ... operations have resumed, and the company expects to return ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
Breaking Medicine News(10 mins):